STOCK TITAN

Labcorp Completes Acquisition of Toxikon Corporation

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)

BURLINGTON, N.C.--(BUSINESS WIRE)-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services. The addition of Toxikon to Labcorp Drug Development bolsters Labcorp’s strong nonclinical development portfolio, and creates a strategic footprint for the company to partner with pharmaceutical and biotechnology clients in the Boston, Mass., area.

The definitive agreement for the transaction was announced on Nov. 18. Specific terms were not disclosed.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY 2020. Learn more about Labcorp at www.Labcorp.com, or follow us on LinkedIn and Twitter @Labcorp.

Labcorp Contacts:

Media: Christopher Allman-Bradshaw – 336-436-8263

Media@Labcorp.com



Investors: Chas Cook – 336-436-5076

Investor@Labcorp.com

Source: Labcorp

FAQ

What is the significance of Labcorp's acquisition of Toxikon Corporation?

The acquisition of Toxikon enhances Labcorp's nonclinical development portfolio and strengthens its strategic footprint in the pharmaceutical and biotechnology sectors.

When was the acquisition agreement for Toxikon Corporation announced?

The acquisition agreement was announced on November 18.

What impact will the Toxikon acquisition have on Labcorp?

The acquisition is expected to bolster Labcorp's capabilities in delivering nonclinical testing services.

What is Labcorp's revenue for FY 2020?

Labcorp reported a revenue of $14 billion in FY 2020.

Where is Labcorp enhancing its services with the Toxikon acquisition?

Labcorp is enhancing its services in the Boston, Massachusetts area.
Labcorp Holdings Inc

NYSE:LH

LH Rankings

LH Latest News

LH Stock Data

19.08B
83.32M
0.34%
96.06%
2.21%
Diagnostics & Research
Services-medical Laboratories
Link
United States
BURLINGTON